MedTrace Logo

Hypnosis Induction and Height Experience in VR - Control Group Comparison and Three Sessions

NCT06618456 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2024-10-01

No results posted yet for this study

Summary

This study attempts to test wether a VR-supported trance induction and a subsequent exposure to altitude in VR with hypnotic suggestions via Audio reduces acrophobia more than a control-group intervention without trance induction. Furthermore the study attempts to test if three sessions of the interventions within three weeks can lead to a stronger reduction of acrophobia than only one session.

Participants will be selected via an online survey according to their score on the Height Interpersonal Questionnaire (HIQ). At the start of the study, participants will be screened by professional clinicians for any mental disorders. In the laboratory they will undergo one of the two interventions in VR (experimental group / control group) and complete questionnaires for three times within three weeks. On a separate day within these three weeks they will be placed in a 30-minute trance to test their suggestibility.

Conditions

  • Acrophobia

Interventions

BEHAVIORAL

VR dive (with Hypnosis)

Participants experience a VR dive through a friendly underwater world. They get a trance induction via audio.

BEHAVIORAL

VR dive (without Hypnosis)

Participants experience a VR dive through a friendly underwater world. They are informed that this part of the VR is a familiarization phase to the VR and they do not get a trance induction.

BEHAVIORAL

Height exposure

The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.

Sponsors & Collaborators

  • Milton Erickson Gesellschaft für klinische Hypnose

    collaborator UNKNOWN

  • Milton Erickson Gesellschaft Stiftung

    collaborator UNKNOWN

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Dirk Revenstorf, Prof. · University Hospital Tuebingen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-07
Primary Completion
2024-07-22
Completion
2024-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06618456 on ClinicalTrials.gov